A novel peptide from human apolipoprotein(a) Inhibits angiogenesls and tumor growth by targeting c-Src phosphorylation in VEGF-induced human umbilical endothelial cells

International Journal of Cancer

Volumn 124, Issue 4, 2009, Pages 843-852

  Yi, Zheng Fang ^a   Cho, Sung Gook ^b,c,e   Hui, Zhao ^d   Wu, Yuan Yuan ^a   Jian, Luo ^a   Dali, Li ^a   Tingfang, Yi ^b,e   Xun, Xu ^d   Zirong, Wu ^a   Mingyao, Liu ^a,b,c,e  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

^e TEXAS A AND M UNIVERSITY SYSTEM   (United States)

Author keywords

Angiogenesis inhibitor; C Src; Peptide; Tumor model

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; APOLIPOPROTEIN A; ARGINYLASPARAGINYLPROLYLASPARTYLGLYCYLASPARTYLISOLEUCYL ASPARAGINYLGLYCYLPROLYLTRYPTOPHAN; FOCAL ADHESION KINASE; GLUTAMINYLGLUTAMYLTRYPTOPHYLALANYLALANYLGLUTAMINYLGLUTAMYLPROLYL HISTIDYLARGINYLHISTIDYLSERYLTHREONYLPHENYLALANYLISOLEUCYLPROLYL GLYCYLTHREONYLASPARAGINYLLYSYLASPARAGINYLALANYLGLYCYLLEUCYLGLUTAMYLLYSYL ASPARAGINYLTYROSINE; METHIONYLPHENYLALANYLGLYCYLASPARAGINYLGLYCYLLYSYLGLYCYLTYROSYL ARGINYLGLYCYLLYSYLLYSYLALANYLTHREONYLTHREONYLVALYLTHREONYLGLYCYLTHREONYLPROLINE; MITOGEN ACTIVATED PROTEIN KINASE; P21 ACTIVATED KINASE 1; PEPTIDE KV11; PROTEIN TYROSINE KINASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; KV11 PEPTIDE, HUMAN; PEPTIDE; PEPTIDE FRAGMENT; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CHORIOALLANTOIS; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DOWN REGULATION; DRUG EFFECT; DRUG FATALITY; DRUG MECHANISM; DYING; EMBRYO; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INFLAMMATION; METASTASIS; MOUSE; NONHUMAN; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SEVERE COMBINED IMMUNODEFICIENCY; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UMBILICUS; VASCULAR ENDOTHELIUM; WEIGHT REDUCTION; WOUND HEALING; ANIMAL; C57BL MOUSE; CHEMISTRY; CHICKEN; CYTOLOGY; METABOLISM; MOUSE MUTANT; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; UMBILICAL VEIN;

ANIMALS; APOLIPOPROTEINS A; APOPROTEIN(A); CHICKENS; CHORIOALLANTOIC MEMBRANE; ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED C57BL; MICE, SCID; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PEPTIDES; PHOSPHORYLATION; SRC-FAMILY KINASES; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58149473461     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24027     Document Type: Article

References (31)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
2. Folkman J. 'The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65-71.
3. Carmeliet P, Collen D. Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ami N Y Acad Sei 9021249-62, 2000; discussion 62-4.
4. Noguera-Troise I, Dalv C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Ya'ncopoulos GD, Thurston G. Blockade of D114 inhibits tumour growth bv promoting non-productive angiogenesis. Nature 2006;444:1032-7.
5. Zacharv I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 2003:31:1171-7.
6. Nguyen NO, Tabruyn SP, Litis L, Lion M, Cornet AM, Lair F, Rentier-Delrue F, Brasseur R, Martial JA, Struman I. Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis. Proc Natl Acad Sci USA 2006:103; 14319-24
7. Kim JS, Yu HK, Alin JH, Lee HJ, Hong SW, Jung KH, Chang SI, Hong YK, Joe YA, Byun SM, Lee SK, Chung SI, et al. Human apoli poprotein (a) kringle V inhibits angiogenesis in vitro and in vivo by interfering with the activation of focal adhesion kinases. Biochem Biophvs Res Comraun 2004;313:534-40.
8. Kim JS, Chang JH, Yu HK, Ahn JH, Yum JS, Lee SK, Jung KH, Park DH, Yoon Y, Byun SM, Chung SI. Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a). J Biol Cliem 2003:278: 29000-8.
9. Gasteiger E. Gattiker A, Hoogland C, Ivanyi I, Appel RD, Bairoch A. ExPASy: The proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res 2003:31:3784-8.
10. Trousdale RK, Pollak SV, Klein J, Lobel L, Funahashi Y, Feirt N, Lustbader JW. Single-chain bifunctional vascular endothelial growth factor (VEGF)-follicle-stimulating hormone (FSH)-C-terminal peptide (CTPi is superior to the combination therapy of recombinant VEGF plus FSH-CTP in stimulating angiogenesis during ovarian folliculogenesis. Endocrinology 2007; 148:1296-305.
11. Wang J, Wilcken DE, Wang XL. Cigarette smoke activates easpase-3 to induce apoptosis of human umbilical venous endothelial cells. Mol Genet Metab 2001;72:82-8.
12. Yi T, Yi Z, Cho SG, Luo J, Pandey MK, Aggarwal BB, Liu M. Gambogie acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res 2008;68:1843-50.
13. Stafford LJ, Xia C, Ma W, Cai Y, Liu M. Identification and characterization of mouse metastasis-suppressor KiSSl and its G-protein-coupled receptor. Cancer Res 2002;62:5399-404.
14. Dhanabal M, LaRochelle WJ, Jeffers M, Herrmann J, Rastelli L, McDonald WF, Chillakuru RA, Yang M, Boldog FL, Padigaru M, McQueeney KD, Wu F, et al. Angioarrestin: an antiangiogenic protein with tumor-inhibiting properties. Cancer Res 2002;62:3834-41.
15. Kuo CJ, LaMontagne KR, Jr., Garcia-Cardena G, Ackley BD, Kalman D, Park S, Christofferson R, Kamihara J, Ding YH, Lo KM, Gillies S, Folkman J, et al. Oligomerization-dependent regulation of motility and morphogenesis by the collagen XVIII NC1/endostatin domain. J Cell Biol 2001;152:1233-46.
16. Miller WJ, Kayton ML, Patton A, O'Connor S, He M, Vu H, Baibakov G, Lorang D, Knezevic V, Kohn E, Alexander HR, Stirling D, et al. A novel technique for quantifying changes in vascular density, endothelial cell proliferation and protein expression in response to modulators of angiogenesis using the chick chorioallantoic membrane (CAM) assay. J Trans 1 Med 2004;2:4.
17. Cao R, Wu HL, Veitonmaki N, Linden P, Farnebo J, Shi GY, Cao Y. Suppression of angiogenesis and tumor growth by the inhibitor Kl-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci USA 1999;96:5728-33.
18. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sei 1996;37:1625-32.
19. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997;64:971-8.
20. Wu PC, Yang LC, Kuo HK, Huang CC, Tsai CL, Lin PR, Wu PC, Shin SJ, Tai MH. Inhibition of corneal angiogenesis by local application of vasostatin. Mol Vis 2005;11:28-35.
21. Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, Wang Y, Sethi G, Aggarwal BB, Liu M. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulatedkinase signaling pathways. Mol Cancer Ther 2008;7:1789-96.
22. Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T, Cao Y. Adiponectin-induced antiangiogenesis and antitumor activity involve easpase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 2004;101:2476-81.
23. Don AS, Kisker O, Dilda P, Donoghue N, Zhao X, Decollogne S, Creighton B, Flynn E, Folkman J, Hogg PJ. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 2003;3:497-509.
24. Zhang G, Dass CR, Sumithran E, Di Girolamo N, Sun LQ, Khachigian LM. Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst 2004:96:683-96.
25. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Oftori JA, Mullin RJ, Gilmer TM, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a mukikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6:2012-21.
26. Tournaire R, Simon MP, le Noble F, Eichmann A, England P, Pouyssegur J. A short synthetic peptide inhibits signal transduction, migration and angiogenesis mediated by Tie2 receptor. EMBO Rep 2004;5:262-7.
27. Kruger EA, Duray PH, Price DK, Pluda JM, Figg WD. Approaches to preclinical screening of antiangiogenic agents. Semin Oncol 2001: 28:570-6.
28. Ye H, Jin L, Hu R, Yi Z, Li J, Wu Y, Xi X, Wu Z. Poly(gamma, L-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. Biomaterials 2006;27:5958-65.
29. Roy H. Bhardwaj S. Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett 2006;580:2879-87.
30. Sundberg-Sraith LJ, Doherty JT, Mack CP, Taylor JM. Adhesion stimulates direct PAK1/ERK2 association and leads to ERK-dependent PAK1 Thr212 phosphorylation. J Biol Chem 2005:280:2055-64.
31. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function, Nat Rev Mol Cell Biol 2006:7:359-71